Imetelstat
Sponsors
Gcp-Service International West GmbH, Geron Corp., Geron Corporation, National Cancer Institute (NCI), NCIC Clinical Trials Group
Conditions
AML and MDS patients failing or being refractory to hypomethylating agent (HMA)-based treatmentEssential ThrombocythemiaLymphomaMyelodysplastic SyndromesMyelodysplastic syndromes (MDS)MyelofibrosisMyeloid MalignanciesNeuroblastoma
Phase 1
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
WithdrawnNCT01568632
Start: 2012-03-31End: 2012-10-31Updated: 2012-11-21
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
WithdrawnNCT01916187
Start: 2013-07-30End: 2014-01-16Updated: 2020-09-21
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
RecruitingNCT06247787
Start: 2025-02-04End: 2026-06-30Target: 36Updated: 2026-02-24
Imetelstat Combinations in Relapsed AML
RecruitingNCT07320235
Start: 2026-01-31End: 2035-06-15Target: 36Updated: 2026-01-06
Phase 2
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
CompletedNCT01137968
Start: 2010-05-31End: 2013-09-30Updated: 2016-01-26
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
CompletedNCT01243073
Start: 2010-12-31End: 2015-04-30Updated: 2016-01-26
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
CompletedNCT01731951
Start: 2012-10-29End: 2018-05-24Updated: 2021-09-21
A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based therapy.
WithdrawnCTIS2022-500721-32-00
Target: 30Updated: 2023-01-27
A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based therapy.
Active, not recruitingCTIS2022-500721-32-01
Start: 2023-05-03Target: 30Updated: 2025-10-01
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Active, not recruitingCTIS2024-511348-25-00
Start: 2015-12-11Target: 164Updated: 2025-12-19
Phase 3
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Active, not recruitingNCT04576156
Start: 2021-04-12End: 2028-06-30Updated: 2025-12-04
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Active, not recruitingCTIS2023-509120-17-00
Start: 2021-04-12Target: 260Updated: 2025-11-13